![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » RAYMEDICA RECEIVES FDA APPROVAL TO INITIATE
RAYMEDICA RECEIVES FDA APPROVAL TO INITIATE
June 29, 2006
Raymedica today announced that it has received FDA approval to begin enrolling patients in a US clinical study to evaluate the potential benefits of its HydraFlex Nucleus Arthroplasty System, a new non-fusion technology for the treatment of degenerative disc disease. Implanted via an Anterior lateral RetroPeritoneal Approach (ARPA), the HydraFlex device is designed to replace the diseased nucleus potentially providing pain relief and maintaining disc height. Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20060629005044&newsLang=en)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct